Drug Profile

Research programme: small molecule therapeutics - Orionis Biosciences/University of Texas MD Anderson Cancer Center

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Orionis Biosciences; University of Texas M. D. Anderson Cancer Center
Developer Orionis Biosciences
Class Antineoplastics; Small molecules
Mechanism of Action Protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Apr 2025 No recent reports of development identified for research development in Cancer in USA
10 Mar 2021 Orionis Biosciences and University of Texas MD Anderson Cancer Center agree co-develop small molecule therapeutics in Cancer
10 Mar 2021 Small molecule therapeutics - Orionis Biosciences/The University of Texas MD Anderson Cancer Center is available for licensing as of 10 Mar 2021. https://orionisbio.com/approach/

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com